The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Abstract
Cyclins and cyclin-dependent protein kinases (CDKs) are important proteins that are required for the regulation and expression of the large number of components necessary for the passage through the cell cycle. The concentrations of the CDKs are generally constant, but their activities are controlled by the oscillation of the cyclin levels during each cell cycle. Additional CDK family members play significant roles in a wide range of activities including gene transcription, metabolism, and neuronal function. In response to mitogenic stimuli, cells in the G1-phase of the cell cycle produce D type cyclins that activate CDK4/6. These activated enzymes catalyze the monophosphorylation of the retinoblastoma protein. Subsequently, CDK2-cyclin E catalyzes the hyperphosphorylation of Rb that promotes the release and activation of the E2F transcription factor, which in turn lead to the biosynthesis of dozens of proteins required for cell cycle progression. Consequently, cells pass the G1-restriction point and are committed to complete cell division in the absence of mitogenic stimulation. CDK2-cyclin A, CDK1-cyclin A, and CDK1-cyclin B are required for S-, G2-, and M-phase progression. A crucial mechanism in controlling cell cycle progression is the precise timing of more than 32,000 phosphorylation and dephosphorylation reactions catalyzed by a network of protein kinases and phosphoprotein phosphatases as determined by mass spectrometry. Increased cyclin or CDK expression or decreased levels of endogenous CDK modulators/inhibitors such as INK4 or CIP/KIP have been observed in a wide variety of carcinomas, hematological malignancies, and sarcomas. The pathogenesis of neoplasms because of mutations in the CDKs are rare. Owing to their role in cell proliferation, CDKs represent natural targets for anticancer therapies. Palbociclib, ribociclib, and abemaciclib are FDA-approved CDK4/6 inhibitors used in the treatment of breast cancer. These drugs have IC50 values for CKD4/6 in the low nanomolar range. These inhibitors bind in the cleft between the N-terminal and C-terminal lobes of the CDKs and they inhibit ATP binding. Like ATP, these agents form hydrogen bonds with hinge residues that connect the small and large lobes of protein kinases. Like the adenine base of ATP, these antagonists interact with catalytic spine residues CS6, CS7, and CS8. These and other CDK antagonists are in clinical trials for the treatment of a wide variety of malignancies. As inhibitors of the cell cycle, it is not surprising that one of their most common toxicities is myelosuppression with decreased neutrophil production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Hanks, S. K., & Hunter, T. R. (1995) · PubMed · Cited by 2,518
The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1
Hanks, S. K., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768349 · Cited by 2,318
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862342 · Cited by 1,759
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Malumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Self-citationEvans, T., Rosenthal, E. T., Youngblom, J., Distel, D., & Hunt, T. (1983) · Cell · doi:10.1016/0092-8674(83)90420-8 · Cited by 1,516
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,487
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Ubiquitin ligases: cell-cycle control and cancer
Nakayama, K. I., & Nakayama, K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1881 · Cited by 1,433
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Mammalian cyclin-dependent kinases
Malumbres, M., & Barbacid, M. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.09.005 · Cited by 1,295
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Sibling rivalry in the E2F family
Trimarchi, J. M., & Lees, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm714 · Cited by 1,158
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862343 · Cited by 960
Protein kinases: evolution of dynamic regulatory proteins
Taylor, S. S., & Kornev, A. P. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.09.006 · Cited by 945
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Self-citationHortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy155 · Cited by 876
Genetic control of cell size at cell division in yeast
Nurse, P. (1975) · Nature · doi:10.1038/256547a0 · Cited by 861
Kornev, A. P., Haste, N. M., Taylor, S. S., & Ten Eyck, L. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607656103 · Cited by 762
Rajagopalan, H., & Lengauer, C. (2004) · Nature · doi:10.1038/nature03099 · Cited by 725
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J., Barlogie, B., & Shaughnessy, J. (2005) · Blood · doi:10.1182/blood-2005-01-0034 · Cited by 698
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Self-citationThe DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
Goldstein, M., & Kastan, M. B. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-081313-121208 · Cited by 590
Genetic Control of the Cell-Division Cycle in Yeast, I. Detection of Mutants
Hartwell, L. H., Culotti, J., & Reid, B. (1970) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.66.2.352 · Cited by 561
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Brown, N. R., Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (1999) · Nature Cell Biology · doi:10.1038/15674 · Cited by 546
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
A historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Self-citationThrough the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
Zuccotto, F., Ardini, E., Casale, E., & Angiolini, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901443h · Cited by 518
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 487
Self-citationA census of amplified and overexpressed human cancer genes
Santarius, T., Shipley, J., Brewer, D., Stratton, M. R., & Cooper, C. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2771 · Cited by 482
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Sicinski, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 461
A helix scaffold for the assembly of active protein kinases
Kornev, A. P., Taylor, S. S., & Ten Eyck, L. F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807988105 · Cited by 442
Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 433
Drexler, H. (1998) · Leukemia · doi:10.1038/sj.leu.2401043 · Cited by 426
Shah, K., Liu, Y., Deirmengian, C., & Shokat, K. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3565 · Cited by 417
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
RAF protein-serine/threonine kinases: Structure and regulation
Roskoski, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.092 · Cited by 376
Self-citationJanus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 373
Self-citationTen things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275
Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., & Sausville, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.22.1736 · Cited by 346
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
The dynamic control of signal transduction networks in cancer cells
Kolch, W., Halasz, M., Granovskaya, M., & Kholodenko, B. N. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3983 · Cited by 339
Steroid-hormone receptors in breast cancer
Wittliff, J. L. (1984) · Cancer · doi:10.1002/1097-0142(19840201)53:3+<630::aid-cncr2820531308>3.0.co;2-3 · Cited by 325
INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions
Cánepa, E. T., Scassa, M. E., Ceruti, J. M., Marazita, M. C., Carcagno, A. L., Sirkin, P. F., & Ogara, M. F. (2007) · IUBMB Life · doi:10.1080/15216540701488358 · Cited by 312
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Self-citationKLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
van Linden, O. P. J., Kooistra, A. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400378w · Cited by 298
The Molecular Balancing Act of p16INK4a in Cancer and Aging
LaPak, K. M., & Burd, C. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0350 · Cited by 291
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Bassermann, F., Eichner, R., & Pagano, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.02.028 · Cited by 268
Roskoski, R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.010 · Cited by 260
Self-citationVijayan, R. S. K., He, P., Modi, V., Duong-Ly, K. C., Ma, H., Peterson, J. R., Dunbrack, R. L., & Levy, R. M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501603h · Cited by 245
CDK1 structures reveal conserved and unique features of the essential cell cycle CDK
Brown, N. R., Korolchuk, S., Martin, M. P., Stanley, W. A., Moukhametzianov, R., Noble, M. E. M., & Endicott, J. A. (2015) · Nature Communications · doi:10.1038/ncomms7769 · Cited by 239
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
Self-citationLin, T. S., Ruppert, A. S., Johnson, A. J., Fischer, B., Heerema, N. A., Andritsos, L. A., Blum, K. A., Flynn, J. M., Jones, J. A., Hu, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6944 · Cited by 222
Mendrzyk, F., Radlwimmer, B., Joos, S., Kokocinski, F., Benner, A., Stange, D. E., Neben, K., Fiegler, H., Carter, N. P., Reifenberger, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8589 · Cited by 213
Deciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
Meharena, H. S., Chang, P., Keshwani, M. M., Oruganty, K., Nene, A. K., Kannan, N., Taylor, S. S., & Kornev, A. P. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001680 · Cited by 208
Karst, A. M., Jones, P. M., Vena, N., Ligon, A. H., Liu, J. F., Hirsch, M. S., Etemadmoghadam, D., Bowtell, D. D. L., & Drapkin, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2247 · Cited by 208
Nakayama, N., Nakayama, K., Shamima, Y., Ishikawa, M., Katagiri, A., Iida, K., & Miyazaki, K. (2010) · Cancer · doi:10.1002/cncr.24987 · Cited by 201
PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials
Carles, F., Bourg, S., Meyer, C., & Bonnet, P. (2018) · Molecules · doi:10.3390/molecules23040908 · Cited by 197
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Self-citationTaylor, S. S., Radzio‐Andzelm, E., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.13.7557015 · Cited by 188
Approaches to discover non-ATP site kinase inhibitors
Gavrin, L. K., & Saiah, E. (2013) · MedChemComm · doi:10.1039/c2md20180a · Cited by 184
New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Lamba, V., & Ghosh, I. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800672813 · Cited by 182
Lücking, U., Jautelat, R., Krüger, M., Brumby, T., Lienau, P., Schäfer, M., Briem, H., Schulze, J., Hillisch, A., Reichel, A., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300096 · Cited by 182
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Paruch, K., Dwyer, M. P., Alvarez, C., Brown, C., Chan, T.-Y., Doll, R. J., Keertikar, K., Knutson, C., McKittrick, B., Rivera, J., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100051d · Cited by 175
Zindy, F., Cunningham, J. J., Sherr, C. J., Jogal, S., Smeyne, R. J., & Roussel, M. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13462 · Cited by 172
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J., White, H. S., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 170
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.021 · Cited by 170
Self-citationMita, M. M., Joy, A. A., Mita, A. C., Sankhala, K. K., Jou, Y., Zhang, D., Statkevich, P., Zhu, Y., Yao, S., Small, K. A., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.016 · Cited by 156
A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src
Liu, Y., Shah, K., Yang, F., Witucki, L. A., & Shokat, K. M. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00099-6 · Cited by 156
Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors
Starostina, N. G., & Kipreos, E. T. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.004 · Cited by 147
Santo, L., Vallet, S., Hideshima, T., Cirstea, D. D., Ikeda, H., Pozzi, S., Patel, K. J., Okawa, Y., Görgün, G., Perrone, G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.510 · Cited by 145
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers
Santo, L., Siu, K. T., & Raje, N. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.024 · Cited by 142
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.022 · Cited by 138
Self-citationHighlights of the Latest Advances in Research on CDK Inhibitors
Cicenas, J., Kalyan, K. P., Sorokinas, A., Jatulyte, A., Valiūnas, D., Kaupinis, A., & Valius, M. (2014) · Cancers · doi:10.3390/cancers6042224 · Cited by 135
Bisi, J., Sorrentino, J. A., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0775 · Cited by 135
Nemunaitis, J. J., Small, K. A., Kirschmeier, P. T., Zhang, D., Zhu, Y., Jou, Y., Statkevich, P., Yao, S., & Bannerji, R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-259 · Cited by 134
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.007 · Cited by 133
Self-citationZindy, F., den Besten, W., Chen, B., Rehg, J. E., Latres, E., Barbacid, M., Pollard, J. W., Sherr, C. J., Cohen, P. E., & Roussel, M. F. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.9.3244-3255.2001 · Cited by 131
O’Shaughnessy, J., Petráková, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D., Hart, L. L., Villanueva, C., Jakobsen, E. H., Beck, J. T., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4518-8 · Cited by 124
Flynn, J. M., Jones, J. A., Johnson, A. J., Andritsos, L. A., Maddocks, K. J., Jaglowski, S. M., Hessler, J. D., Grever, M. R., Im, E., Zhou, H., et al. (2015) · Leukemia · doi:10.1038/leu.2015.31 · Cited by 123
Shah, A., Bloomquist, E. W., Tang, S. W., Fu, W., Bi, Y., Liu, Q., Yu, J., Zhao, P., Palmby, T. R., Goldberg, K. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2369 · Cited by 123
Pyrido[2,3- d ]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4
VanderWel, S. N., Harvey, P. J., McNamara, D. J., Repine, J. T., Keller, P. R., Quin, J., Booth, R. J., Elliott, W. L., Dobrusin, E. M., Fry, D. W., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049355+ · Cited by 119
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.009 · Cited by 119
Self-citationRole of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
Roskoski, R. J., & Sadeghi‐Nejad, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.021 · Cited by 118
Self-citationGuidelines for preparing color figures for everyone including the colorblind
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.005 · Cited by 112
Self-citationZeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.125849 · Cited by 105
Redefining the Protein Kinase Conformational Space with Machine Learning
Ung, P. M. U., Rahman, R., & Schlessinger, A. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.05.002 · Cited by 104
Stephenson, J., Nemunaitis, J. J., Joy, A. A., Martin, J., Jou, Y., Zhang, D., Statkevich, P., Yao, S., Zhu, Y., Zhou, H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.020 · Cited by 101
On the Concentrations of Cyclins and Cyclin-Dependent Kinases in Extracts of Cultured Human Cells
Arooz, T., Yam, C. H., Siu, W. Y., Lau, A. W. S., Li, K. K. W., & Poon, R. Y. C. (2000) · Biochemistry · doi:10.1021/bi0009643 · Cited by 100
Dey, J., Deckwerth, T. L., Kerwin, W. S., Casalini, J. R., Merrell, A., Grenley, M. O., Burns, C., Ditzler, S. H., Dixon, C., Beirne, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-18368-w · Cited by 99
Nasmyth, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00604-3 · Cited by 93
Wang, J., Li, Q., Yuan, J., Wang, J., Chen, Z., Liu, Z., Li, Z., Lai, Y., Gao, J., & Shen, L. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1231-7 · Cited by 92
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
Guarducci, C., Bonechi, M., Boccalini, G., Benelli, M., Risi, E., Leo, A. D., Malorni, L., & Migliaccio, I. (2017) · Breast Care · doi:10.1159/000484167 · Cited by 91
Mahadevan, D., Plummer, R., Squires, M. S., Rensvold, D., Kurtin, S. E., Pretzinger, C., Dragovich, T., Adams, J., Lock, V., Smith, D.-M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq734 · Cited by 90
Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Bajusz, D., Ferenczy, G. G., & Keserű, G. M. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170224121313 · Cited by 88
Ayaz, P., Andres, D., Kwiatkowski, D., Kolbe, C., Lienau, P., Siemeister, G., Lücking, U., & Stegmann, C. M. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00074 · Cited by 85
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Fischer, P. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 84
Participation of ADP Dissociation in the Rate-Determining Step in cAMP-Dependent Protein Kinase
Zhou, J., & Adams, J. A. (1997) · Biochemistry · doi:10.1021/bi971438n · Cited by 83
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.020 · Cited by 80
Self-citationCDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Lynce, F. C., Shajahan‐Haq, A. N., & Swain, S. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.008 · Cited by 80
Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma
Kuhn, E., Bahadirli-Talbott, A., & Shih, I. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.209 · Cited by 79
Karp, J. E., Smith, B. D., Resar, L. M. S., Greer, J. M., Blackford, A. L., Zhao, M., Nelson, D. M., Alino, K., Levis, M. J., Gore, S. D., et al. (2011) · Blood · doi:10.1182/blood-2010-09-310862 · Cited by 78
Kwarcinski, F. E., Brandvold, K. R., Phadke, S., Beleh, O. M., Johnson, T. K., Meagher, J. L., Seeliger, M. A., Stuckey, J. A., & Soellner, M. B. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01018 · Cited by 75
Chen, E. X., Hotte, S. J., Hirte, H. W., Siu, L. L., Lyons, J., Squires, M. S., Lovell, S., Turner, S., McIntosh, L., & Seymour, L. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.565 · Cited by 72
Jacobsen, D. M., Bao, Z., O’Brien, P., Brooks, C. L., & Young, M. A. (2012) · Journal of the American Chemical Society · doi:10.1021/ja304419t · Cited by 70
Gupta, P., Zhang, Y., Zhang, X., Wang, Y., Lu, K. W., Hall, T., Peng, R., Yang, D., Xie, N., & Chen, Z. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487578 · Cited by 67
Seftel, M. D., Kuruvilla, J. G., Kouroukis, T., Banerji, V., Fraser, G. A. M., Crump, M., Kumar, R., Chalchal, H. I., Salim, M., Laister, R. C., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239259 · Cited by 51
Lanasa, M. C., Andritsos, L. A., Brown, J. R., Gabrilove, J. L., Caligaris‐Cappio, F., Ghia, P., Larson, R. A., Kipps, T. J., Leblond, V., Milligan, D. W., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.02.001 · Cited by 48
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
Palumbo, A., Lau, G., & Saraceni, M. M. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018795146 · Cited by 44
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment
Parylo, S., Vennepureddy, A., Dhar, V., Patibandla, P., & Sokoloff, A. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218770904 · Cited by 42
Profile of abemaciclib and its potential in the treatment of breast cancer
Martin, J., & Goldstein, L. J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s149245 · Cited by 42
Targeting CDK4/6 pathways and beyond in breast cancer
Ribnikar, D., Volovăț, S. R., & Cardoso, F. (2018) · The Breast · doi:10.1016/j.breast.2018.10.001 · Cited by 40
Cyclin alterations in diverse cancers: outcome and co-amplification network
Schwaederle, M. C., Daniels, G. A., Piccioni, D. E., Fanta, P. T., Schwab, R. B., Shimabukuro, K. A., Parker, B. A., & Kurzrock, R. (2014) · Oncotarget · doi:10.18632/oncotarget.2848 · Cited by 39
Wang, Y., Liu, W.-J., Yin, L., Li, H., Chen, Z., Zhu, D., Song, X., Cheng, Z., Song, P. Y., Wang, Z., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.068 · Cited by 33
Bahleda, R., Grilley‐Olson, J. E., Govindan, R., Barlési, F., Greillier, L., Pérol, M., Ray-Coquard, I. L., Strumberg, D., Schultheis, B. S., Dy, G. K., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.92 · Cited by 31
Kinase-Centric Computational Drug Development
Kooistra, A. J., & Volkamer, A. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.001 · Cited by 29
SnapShot: Phosphoregulation of Mitosis
Burgess, A., Vuong, J., Rogers, S., Malumbres, M., & O’Donoghue, S. I. (2017) · Cell · doi:10.1016/j.cell.2017.06.003 · Cited by 14
Cited by
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Roskoski, R. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107059 · Cited by 383
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Roskoski, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105463 · Cited by 335
Self-citationTargeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Self-citation
Metadata
- Authors
- Roskoski, R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 139
- Pages
- 471-488
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2902263717
- Cited by
- 393
- References
- 137
- FWCI
- 14.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.